RxDoctor Payments DataLook up a doctor →

Patrick Miller, MD

Radiation Oncology · Glendale, AZNPI 1023016573

Payments from drug & device makers

$9,738in general payments, 2019–2025

Across 435 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$924
  • Merck$560
  • Johnson & Johnson$469
  • Pfizer$454
  • AbbVie$423
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$1,05011%
  • Food & beverage$8,68889%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)28$1,547
Novartis58$924
Merck25$560
Johnson & Johnson26$469
Pfizer24$454
AbbVie22$423
Amgen21$417
Sanofi20$397
Genentech USA, Inc.14$305
Bayer16$293
Pharmacyclics LLC, An Abbvie Company13$269
Daiichi Sankyo Inc.10$232
Eisai Inc.10$214
Blueprint Medicines Corporation9$212
Lilly USA, LLC9$204
Seagen Inc.10$186
Incyte Corporation10$185
Genmab U.S., Inc.6$159
E.r. Squibb & Sons, L.L.C.8$152
GSK7$150
Takeda Pharmaceuticals U.S.A., Inc.7$148
Exelixis Inc.6$135
Kyowa Kirin, Inc.7$120
Puma Biotechnology, Inc.5$109
Otsuka Pharmaceutical Development & Commercialization, Inc.1$97
Servier Pharmaceuticals LLC4$92
Tersera Therapeutics LLC3$91
Boehringer Ingelheim4$84
Novocure Inc.1$83
Astellas Pharma US Inc4$78
Ipsen Biopharmaceuticals, Inc5$77
Gilead(2 entities)3$61
Deciphera Pharmaceuticals Inc.3$60
Visionrt, Inc.1$59
Rigel Pharmaceuticals, Inc.2$56
Adaptive Biotechnologies Corporation3$55
Regeneron Healthcare Solutions, Inc.2$46
EMD Serono, Inc.3$43
Tactile Systems Technology Inc2$40
AMAG Pharmaceuticals, Inc.2$40
Karyopharm Therapeutics Inc.2$38
CTI Biopharma Corp.1$28
Stemline Therapeutics Inc.1$27
Beone Medicines USA, Inc.1$26
Tolmar, Inc.1$22
ADC Therapeutics America, Inc.1$22
Boston Scientific1$22
Bristol Myers Squibb1$21
Mylan Institutional Inc.1$21
Lexicon Pharmaceuticals, Inc.1$19
Sun Pharmaceutical Industries Inc.1$19
Coherus Oncology, Inc.1$19
G1 Therapeutics, Inc.1$18
Progenics Pharmaceuticals, Inc.1$18
EUSA Pharma (US) LLC1$18
Immunocore Limited1$17
Acrotech Biopharma Inc.1$16
Sobi, Inc1$16
Myovant Sciences Inc.1$15
Verastem, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,738 in reported general payments places this provider in the 80th percentile of 138 radiation oncology providers in Arizona.

See all radiation oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,065,301
Medicare patients
359
Services billed
5,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl14$341
SsdSilver Sulfadiazine15$169

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →